Chien-Yi Hsu
Overview
Explore the profile of Chien-Yi Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin T, Leu H, Wu Y, Tseng W, Lin T, Yeh H, et al.
Biomark Res
. 2025 Feb;
13(1):24.
PMID: 39920870
Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) modulates the enzymatic activity of matrix metalloproteinase-9, which is an important mediator of plaque instability in atherosclerosis. High NGAL levels can independently predict all-cause mortality...
2.
Chang T, Hung C, Ko S, Liao C, Hsu C, Huang N, et al.
Am J Cardiol
. 2024 May;
223:52-57.
PMID: 38763384
The benefits of rapidly up-titrating evidence-based treatments following heart failure (HF) hospitalizations were demonstrated in the The Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart...
3.
Hsu C, Chung F, Chao C, Chen Y, Wu C, Wu Y, et al.
Mayo Clin Proc
. 2024 Mar;
99(6):940-952.
PMID: 38530689
Objective: To investigate whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors (ARNis) in real-world practice because patients with baseline systolic...
4.
Chen K, Hsu C, Wu C, Lin K, Chen S, Lee Y, et al.
Acta Cardiol Sin
. 2023 Nov;
39(6):783-806.
PMID: 38022422
Cardiac rehabilitation is a comprehensive intervention recommended in international and Taiwanese guidelines for patients with acute myocardial infarction. Evidence supports that cardiac rehabilitation improves the health-related quality of life, enhances...
5.
Chen H, Tsai Y, Hsu C, Wang Y, Hsieh C, Chen J, et al.
Biosensors (Basel)
. 2023 Oct;
13(10).
PMID: 37887122
An effective early diagnosis is important for rheumatoid arthritis (RA) management. This study reveals a novel RA detection method using bacteriorhodopsin as a photoelectric transducer, a light-driven proton pump in...
6.
Sung K, Chang H, Hsu N, Huang W, Lin Y, Yun C, et al.
J Am Heart Assoc
. 2023 Sep;
12(18):e028860.
PMID: 37681571
Background The angiotensin receptor-neprilysin inhibitor (LCZ696) has emerged as a promising pharmacological intervention against renin-angiotensin system inhibitor in reduced ejection fraction heart failure (HFrEF). Whether the therapeutic benefits may vary...
7.
Sung H, Hsu C, Lee Y, Lin P, Liao C, Chung F, et al.
J Chin Med Assoc
. 2023 Jun;
86(8):725-731.
PMID: 37314316
Background: Iron deficiency (ID) is a common comorbidity among patients with heart failure and reduced ejection fraction (HFrEF), and is associated with poorer outcomes independent of anemia. This study aimed...
8.
Hsu C, Huang C, Shih C, Lin Y, Huang P, Lin S, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108160
Tumor necrosis factor superfamily 14 (TNFSF14) is also known as the LT-related inducible ligand (LIGHT). It can bind to the herpesvirus invasion mediator and lymphotoxin-β receptor to perform its biological...
9.
Ou S, Chao C, Tsai M, Lee K, Tseng W, Bin P, et al.
Heart
. 2022 Nov;
109(2):134-142.
PMID: 36371660
Objective: Heart failure (HF) imposes a substantial burden and the prevalence of HF is high in patients with chronic kidney disease (CKD). HF results in multiple hospital admissions, but whether...
10.
Liao C, Toh H, Yang C, Hsu C, Lee M, Chang W, et al.
Hypertens Res
. 2022 Oct;
46(1):187-199.
PMID: 36229527
With the promising cardiovascular benefits in the STEP and SPRINT trials, the 2022 Taiwan's hypertension guidelines redefined the hypertension threshold as 130/80 mmHg and a universal blood-pressure target of <130/80 ...